Award Year / Program / Phase:1996 / SBIR / Phase II
Agency:HHS
Principal Investigator:Alexey Margolin
Award Amount:$495,146.00
Abstract:
Enzyme microcrystals (less than 100 um) grown from aqueous solution and cross-linked witha bifunctional agent such as glutaraldehyde exhibit remarkable characteristics that are superior to bothsoluble and conventionally immobilized enzymes. Such cross-linked enzyme crystals (CLECs) remainactive in… More
Award Year / Program / Phase:2001 / SBIR / Phase I
Agency:HHS
Principal Investigator:Bhami C. Shenoy
Award Amount:$100,083.00
Abstract:
Design of new efficient drug delivery systems for proteins is one of the
major themes of modern biotechnology and biopharmaceutical industry.
We found that crosslinked enzyme crystals (CLECs(R)) show stability
under low pH, on storage and against proteolysis. The CLECs can be
prepared in high yield… More
Award Year / Program / Phase:2001 / SBIR / Phase I
Agency:HHS
Principal Investigator:Bhami C. Shenoy
Award Amount:$86,724.00
Abstract:
DESCRIPTION (provided by applicant): Design of new efficient drug delivery
systems for proteins is one of the major themes of modern biotechnology and
biopharmaceutical industry. We found that crosslinked enzyme crystals (CLECs)
show stability under low pH, on storage and… More
DESCRIPTION (provided by applicant): Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that cross-linked enzyme crystals (CLECs) show remarkable stability at various pHs, on storage, against… More
DESCRIPTION (provided by applicant): Design of stable and efficient formulation of proteins for therapeutic use as drugs has been a major focus of biotechnology and pharmaceutical companies. In the Phase I grant, we developed a stable, active formulation of protease from Aspergillus melleus,… More
DESCRIPTION (provided by applicant): Design of stable and efficient formulation of proteins for therapeutic use as drugs has been a major focus of biotechnology and pharmaceutical companies. In the Phase I grant, we developed a stable, active formulation of protease from Aspergillus melleus,… More